MA27671A1 - Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement - Google Patents

Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement

Info

Publication number
MA27671A1
MA27671A1 MA28526A MA28526A MA27671A1 MA 27671 A1 MA27671 A1 MA 27671A1 MA 28526 A MA28526 A MA 28526A MA 28526 A MA28526 A MA 28526A MA 27671 A1 MA27671 A1 MA 27671A1
Authority
MA
Morocco
Prior art keywords
rapamycin
treatment
combination
pharmaceutical compositions
derivative
Prior art date
Application number
MA28526A
Other languages
English (en)
Inventor
Henrietta Moore
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27671(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0306070A external-priority patent/GB0306070D0/en
Priority claimed from GB0306868A external-priority patent/GB0306868D0/en
Priority claimed from GB0319226A external-priority patent/GB0319226D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27671A1 publication Critical patent/MA27671A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques comprenant en combinaison la rapamycine ou un dérivé de rapamycine et un composé de formule (I), ces compositions pouvant être utiles dans le traitement de maladies inflammatoires et de maladies induites immunologiquement, telles que les maladies auto-immunes.
MA28526A 2003-03-17 2005-09-30 Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement MA27671A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0306070A GB0306070D0 (en) 2003-03-17 2003-03-17 Organic compounds
GB0306868A GB0306868D0 (en) 2003-03-25 2003-03-25 Organic compounds
GB0319226A GB0319226D0 (en) 2003-08-15 2003-08-15 Organic compounds

Publications (1)

Publication Number Publication Date
MA27671A1 true MA27671A1 (fr) 2005-12-01

Family

ID=33032928

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28526A MA27671A1 (fr) 2003-03-17 2005-09-30 Compositions pharmaceutiques comprenant une combinaison de rapamycine ou de son derive et de pimecrolimus pour le traitement de maladies inflammatoires et de maladies induites immunologiquement

Country Status (25)

Country Link
US (1) US20060154952A1 (fr)
EP (1) EP1608368B8 (fr)
JP (1) JP2006515017A (fr)
KR (1) KR100855140B1 (fr)
AR (1) AR043504A1 (fr)
AT (1) ATE409479T1 (fr)
AU (1) AU2004222563B2 (fr)
BR (1) BRPI0408423A (fr)
CA (2) CA2633287A1 (fr)
CL (1) CL2004000535A1 (fr)
DE (1) DE602004016830D1 (fr)
EC (1) ECSP056006A (fr)
ES (1) ES2315648T3 (fr)
HR (1) HRP20050800A2 (fr)
IS (1) IS8028A (fr)
MA (1) MA27671A1 (fr)
MX (1) MXPA05009934A (fr)
MY (1) MY137868A (fr)
NO (1) NO20054778L (fr)
PE (1) PE20050313A1 (fr)
PL (1) PL1608368T3 (fr)
PT (1) PT1608368E (fr)
TN (1) TNSN05197A1 (fr)
TW (2) TW200835484A (fr)
WO (1) WO2004082681A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1804779A1 (fr) * 2004-10-28 2007-07-11 Wyeth Utilisation d'un inhibiteur mtor dans le traitement de leiomyomes uterins
CA2719134C (fr) * 2008-03-21 2015-06-30 The University Of Chicago Traitement avec des antagonistes des opioides et des inhibiteurs mtor
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
WO2010085495A1 (fr) * 2009-01-21 2010-07-29 Amgen Inc. Compositions et procédés de traitement de maladies inflammatoires et auto-immunes
RU2449806C1 (ru) * 2010-11-30 2012-05-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения красного плоского лишая слизистой оболочки полости рта
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
CN106061482A (zh) 2013-10-08 2016-10-26 拉姆医疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
NZ724756A (en) * 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
CA2963085C (fr) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. Formulation de rapamycine inhalable pour le traitement de l'hypertension pulmonaire
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
WO2018129364A1 (fr) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
EP3817743A4 (fr) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
CN114555634B (zh) 2019-08-13 2025-01-10 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DE69736750T2 (de) * 1996-07-30 2007-08-16 Novartis Ag Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
JP2005514411A (ja) * 2002-01-10 2005-05-19 ノバルティス アクチエンゲゼルシャフト ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム
EP1501565B1 (fr) * 2002-05-09 2006-11-02 Hemoteq GmbH Composes et procedes pour recouvrir de fa on hemocompatible des surfaces

Also Published As

Publication number Publication date
JP2006515017A (ja) 2006-05-18
CA2517671A1 (fr) 2004-09-30
TW200835484A (en) 2008-09-01
PT1608368E (pt) 2009-01-27
TNSN05197A1 (en) 2007-06-11
MY137868A (en) 2009-03-31
AU2004222563A1 (en) 2004-09-30
BRPI0408423A (pt) 2006-03-21
KR20050110023A (ko) 2005-11-22
PL1608368T3 (pl) 2009-03-31
CL2004000535A1 (es) 2005-01-14
MXPA05009934A (es) 2006-03-21
ATE409479T1 (de) 2008-10-15
TW200503703A (en) 2005-02-01
EP1608368A1 (fr) 2005-12-28
US20060154952A1 (en) 2006-07-13
AR043504A1 (es) 2005-08-03
NO20054778D0 (no) 2005-10-17
AU2004222563B2 (en) 2006-11-02
WO2004082681B1 (fr) 2004-11-25
NO20054778L (no) 2005-12-19
EP1608368B8 (fr) 2009-06-10
ECSP056006A (es) 2006-01-27
WO2004082681A1 (fr) 2004-09-30
CA2633287A1 (fr) 2004-09-30
EP1608368B1 (fr) 2008-10-01
ES2315648T3 (es) 2009-04-01
HRP20050800A2 (en) 2006-11-30
PE20050313A1 (es) 2005-06-14
KR100855140B1 (ko) 2008-08-28
IS8028A (is) 2005-09-15
HK1086743A1 (en) 2006-09-29
DE602004016830D1 (de) 2008-11-13

Similar Documents

Publication Publication Date Title
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
DE602004013563D1 (de) Rantagonisten
EP1539234A4 (fr) Methodes de prevention ou de traitement de malignites cellulaires par administration d'antagonistes de cd2
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
MY145074A (en) Thiazolidin-4-one derivatives
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
EP1605936A4 (fr) Antagonistes du recepteur cgrp d'aryl spirohydantoine
MA32231B1 (fr) Composés organiques
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
EP1641423A4 (fr) Antagonistes du recepteur du cgrp de
MA30406B1 (fr) Nouveaux composes
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
MA29213B1 (fr) Quinolones a substitution macrolones - amino
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
EP1753777A4 (fr) METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LA PREVENTION D'UNE INFECTION PAR LE VIH AU MOYEN DE TRIM5a
MA32931B1 (fr) Compositions antimicrobiennes